| Code | CSB-RA011661MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to Drotokibart, targeting the interleukin-4 receptor (IL4R). IL4R is a type I transmembrane protein that serves as a component of receptor complexes for both IL-4 and IL-13, two key cytokines in type 2 immune responses. Upon ligand binding, IL4R initiates JAK-STAT signaling cascades that promote Th2 cell differentiation, IgE class switching in B cells, and activation of eosinophils and mast cells. Dysregulated IL4R signaling is implicated in various allergic and inflammatory conditions, including atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and eosinophilic esophagitis.
Drotokibart is a therapeutic monoclonal antibody that blocks IL4R alpha subunit, thereby inhibiting both IL-4 and IL-13 signaling pathways. This biosimilar provides researchers with a valuable tool for investigating type 2 inflammatory mechanisms, studying IL4R-mediated immune responses, and exploring potential therapeutic interventions in allergic and inflammatory disease models. The antibody enables detailed examination of IL4R biology and its role in immune regulation.
There are currently no reviews for this product.